Arrowhead Pharmaceuticals, Inc. (ARWR)
70.94
+2.07
(+3.01%)
USD |
NASDAQ |
Dec 11, 11:53
Arrowhead Pharmaceuticals Research and Development Expense (Quarterly): 168.80M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 218.89M |
| Ionis Pharmaceuticals, Inc. | 217.13M |
| Alnylam Pharmaceuticals, Inc. | 358.81M |
| Amgen, Inc. | 1.90B |
| Novartis AG | 2.857B |